How many email patterns does Neuropore Therapies, Inc. use?

Neuropore Therapies, Inc. uses 2 known email patterns.

What domain does Neuropore Therapies, Inc. use for work emails?

Neuropore Therapies, Inc. uses neuropore.com for work email addresses.

Most Common Email Formats at Neuropore Therapies, Inc.

Neuropore Therapies, Inc.'s most common email format is First.Last@neuropore.com (ex. John.Doe@neuropore.com), used for 86% of neuropore.com addresses. Neuropore Therapies, Inc. uses 2 email patterns.

@neuropore.com

2 patterns

Format	Example	Share of neuropore.com
First.Last@neuropore.comMost common	John.Doe@neuropore.com	86%
First@neuropore.com	John@neuropore.com	14%

Frequently Asked Questions

What does Neuropore Therapies, Inc. do?

Neuropore Therapies, Inc. was founded in 2008 and operates in the Pharmaceutical Manufacturing industry, alongside similar companies like Roche, UCB and Bristol Myers Squibb. You can visit neuropore.com or contact Neuropore Therapies, Inc.'s headquarters by phone at

+1-858-273-****

. Explore Neuropore Therapies, Inc.'s company overview page for more information.

What is Neuropore Therapies, Inc.'s email address format?

Neuropore Therapies, Inc.'s email format typically follows the pattern of First.Last@neuropore.com; this email format is used 86% of the time. Other contacts within LeadIQ's database had email formats such as First@neuropore.com. Looking for more contact data? Unlock accurate emails and phone numbers from millions of profiles verified in real-time.

How many employees does Neuropore Therapies, Inc. have currently?

Neuropore Therapies, Inc. has approximately 2 employees as of October 2026. Key team members to contact include Research Chemist: W. W. For more team information and contact data, explore Neuropore Therapies, Inc.'s employee directory with LeadIQ.

Neuropore Therapies, Inc. Email Format

Pharmaceutical ManufacturingCalifornia, United States2-10 Employees

Neuropore Therapies, Inc. is a clinical-stage biopharmaceutical company with a small team based in San Diego, California, focused on discovering and developing novel small-molecule therapeutics for Parkinson’s disease and other neurodegenerative disorders. Its research targets core disease processes, including intracellular accumulation of neurotoxic misfolded proteins and neuroinflammation. The lead clinical candidate, NPT200-11, is an orally bioavailable molecule that aims to prevent early alpha-synuclein aggregation implicated in Parkinson’s disease, with additional preclinical compounds pursuing complementary mechanisms. The NPT200-11 program was licensed to UCB Pharma for development and commercialization. Neuropore Therapies has also engaged in collaborations, including a 2019 partnership with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases identified through artificial intelligence.

Most Common Email Formats at Neuropore Therapies, Inc.

@neuropore.com

Need a specific person's email?

Frequently Asked Questions

What does Neuropore Therapies, Inc. do?

What is Neuropore Therapies, Inc.'s email address format?

How many employees does Neuropore Therapies, Inc. have currently?

Neuropore Therapies, Inc. Email Format

Ready to create more pipeline?

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Most Common Email Formats at Neuropore Therapies, Inc.

@neuropore.com

Need a specific person's email?

Frequently Asked Questions

What does Neuropore Therapies, Inc. do?

What is Neuropore Therapies, Inc.'s email address format?

How many employees does Neuropore Therapies, Inc. have currently?

Neuropore Therapies, Inc. Email Format

Ready to create more pipeline?

Everything for prospecting,in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Everything for prospecting,
in one platform.